Inhibin A Concentrations in the Sera of Young Women During and After Chemotherapy for Lymphoma: Correlation with Ovarian Toxicity

PROBLEM: Inhibin A concentrations in serum may reflect the ovarian granulosa cell compartment. To characterize the correlation between ovarian function after gonadotoxic chemotherapy for Hodgkin's or non‐Hodgkin's lymphoma in young women, the immunoreactive inhibin A concentrations in the sera of these patients was measured before, during, and after the gonadotoxic chemotherapy.

[1]  Z. Blumenfeld,et al.  Prevention of gonadal damage during cytotoxic therapy. , 1997, Annals of medicine.

[2]  D. Norfolk,et al.  Transmission of malignant cells in ovarian grafts. , 1997, Human reproduction.

[3]  A. Trounson,et al.  Oncological implications in the replacement of ovarian tissue. , 1997, Human reproduction.

[4]  S. Linn,et al.  Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. , 1996, Human reproduction.

[5]  S. Bernasconi,et al.  Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 1996, The Journal of clinical endocrinology and metabolism.

[6]  H. Burger,et al.  Biological and immunological characterization of inhibin forms in human plasma. , 1996, The Journal of clinical endocrinology and metabolism.

[7]  N. Groome,et al.  Development and application of a two-site enzyme immunoassay for the determination of 'total' activin-A concentrations in serum and follicular fluid. , 1996, The Journal of endocrinology.

[8]  J. Priddle,et al.  Quantification of inhibin pro-alpha C-containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay. , 1995, The Journal of clinical endocrinology and metabolism.

[9]  E. Lawrence,et al.  Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. , 1995, Biology of reproduction.

[10]  T. Woodruff,et al.  Inhibin, activin and the female reproductive axis. , 1995, Annual review of physiology.

[11]  P. Fowler,et al.  Serum concentrations of dimeric inhibin during the spontaneous human menstrual cycle and after treatment with exogenous gonadotrophin. , 1994, Human reproduction.

[12]  G. Lambert-Messerlian,et al.  Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay. , 1994, The Journal of clinical endocrinology and metabolism.

[13]  D. Baird,et al.  Detection of dimeric inhibin throughout the human menstrual cycle by two‐site enzyme immunoassay , 1994, Clinical endocrinology.

[14]  S. Glaser.  Reproductive factors in Hodgkin's disease in women: a review. , 1994, American journal of epidemiology.

[15]  H. Burger,et al.  Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone. , 1993, Maturitas.

[16]  N. Groome,et al.  Immunoassays for inhibin and its subunits. Further applications of the synthetic peptide approach. , 1993, Journal of immunological methods.

[17]  R. Stahel,et al.  Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  T. Woodruff,et al.  Inhibin and activin measured in human serum. , 1993 .

[19]  S. Shalet,et al.  Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. , 1993, Medical and pediatric oncology.

[20]  M. Youdim,et al.  Growth hormone (GH)-binding protein regulation by estrogen, progesterone, and gonadotropins in human: the effect of ovulation induction with menopausal gonadotropins, GH, and gestation. , 1992, The Journal of clinical endocrinology and metabolism.

[21]  M. Pras,et al.  The Effect of Cyclophosphamide Pulses on Fertility in Patients With Lupus Nephritis , 1992, American journal of reproductive immunology.

[22]  V. Diehl,et al.  Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  A. Nademanee,et al.  High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. , 1992, Blood.

[24]  D. Reid,et al.  Bone mineral density (BMD) in patients with lymphoma: The effects of chemotherapy, intermittent corticosteroids and premature menopause , 1992, Hematological oncology.

[25]  S. Proctor,et al.  Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. , 1991, Blood.

[26]  N. Groome,et al.  Preparation of monoclonal antibodies to the beta A subunit of ovarian inhibin using a synthetic peptide immunogen. , 1991, Hybridoma.

[27]  C. Marosi,et al.  Fertility, pregnancies and offspring complications after bone marrow transplantation. , 1991, Bone marrow transplantation.

[28]  J. Jarrell,et al.  The agonist (d-leu-6,des-gly-10)-LHRH-ethylamide does not protect the fecundity of rats exposed to high dose unilateral ovarian irradiation. , 1991, Reproductive toxicology.

[29]  E. Thiel,et al.  Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. , 1990, Cancer treatment reviews.

[30]  N. Groome,et al.  Monoclonal and polyclonal antibodies reactive with the 1-32 amino terminal sequence of the alpha subunit of human 32K inhibin. , 1990, Hybridoma.

[31]  D. Longo.  The use of chemotherapy in the treatment of Hodgkin's disease. , 1990, Seminars in oncology.

[32]  S. Donaldson,et al.  Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. , 1990, International journal of radiation oncology, biology, physics.

[33]  W. Krause,et al.  Treatment with the Gonadotropin‐Releasinghormone Agonist Buserelin to Protect Spermatogenesis against Cytotoxic Treatment in Young Men/Behandlung zum Schutz der Spermatogenese bei cytotoxischer Therapie mit dem Gonadotropin‐Hormon Agonisten Buserelin , 2009, Andrologia.

[34]  K. Moghissi,et al.  Chemotherapy-induced premature ovarian failure: Mechanisms and prevention , 1989, Steroids.

[35]  U. Keilholz,et al.  Long‐term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders , 1989, Cancer.

[36]  H. Burger,et al.  ADVANCES IN THE PHYSIOLOGY OF INHIBIN AND INHIBIN‐RELATED PEPTIDES , 1988, Clinical endocrinology.

[37]  S. Rivkees,et al.  The relationship of gonadal activity and chemotherapy-induced gonadal damage. , 1988, JAMA.

[38]  J. Byrne,et al.  Effects of treatment on fertility in long‐term survivors of childhood or adolescent cancer , 1988, The New England journal of medicine.

[39]  H. Burger,et al.  Circulating immunoreactive inhibin levels during the normal human menstrual cycle. , 1987, The Journal of clinical endocrinology and metabolism.

[40]  C. Griscelli,et al.  [Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor or hematologic disease]. , 1986, Archives francaises de pediatrie.

[41]  W. LeMaire,et al.  A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. , 1985, Cancer research.

[42]  J. Hainsworth,et al.  Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations , 1985 .

[43]  J. Hainsworth,et al.  Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. , 1985, Blood.

[44]  H. Deeg,et al.  Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. , 1983, Transplantation.

[45]  R. Chapman.  Effect of cytotoxic therapy on sexuality and gonadal function. , 1982, Seminars in oncology.

[46]  W. Vale,et al.  Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. , 1981, The New England journal of medicine.

[47]  L. M. Glodé,et al.  PROTECTION FROM CYCLOPHOSPHAMIDE-INDUCED TESTICULAR DAMAGE WITH AN ANALOGUE OF GONADOTROPIN-RELEASING HORMONE , 1981, The Lancet.

[48]  S. Sutcliffe,et al.  Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. , 1979, JAMA.

[49]  S. Sutcliffe.  Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease. Facts and thoughts. , 1979, JAMA.

[50]  P. H. Jones,et al.  Ovarian failure following abdominal irradiation in childhood. , 1976, British Journal of Cancer.

[51]  Sack Rb.  Letter: Serotyping of E. coli. , 1976, Lancet.

[52]  V. Devita,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1970, Annals of internal medicine.